NATCOPHARM818.80

NATCO Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,657 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations3,998.84,429.54,078.33,484.6
Other Income128.1354.5297.6295.1
Total Income4,126.94,784.04,375.93,779.7
Expenses
+ Cost of Materials Consumed522.5536.2593.5570.7
+ Purchases of Stock-in-Trade151.4166.1203.2193.7
+ Changes in Inventories42.7-12.5-106.2-159.4
+ Employee Benefit Expense525.0594.5687.2697.5
+ Finance Costs19.223.936.746.5
+ Depreciation & Amortisation186.8235.2206.6196.1
+ Other Expenses1,005.8949.21,264.11,130.1
Total Expenses2,453.42,492.62,885.12,675.2
EBITDA1,751.42,196.01,436.51,052.0
EBIT1,564.61,960.81,229.9855.9
Profit
PBT before Exceptional Items1,673.52,291.41,490.81,104.5
Pretax Income1,673.52,291.41,490.81,104.5
+ Current Tax316.5437.6303.5236.6
+ Deferred Tax-31.3-29.6-184.6-145.9
Tax Expense285.2408.0118.990.7
+ Share of Associates & JVs0.00.046.6130.9
Net Income1,388.31,883.41,418.51,144.7
+ Net Income — Continuing Ops1,388.31,883.41,371.91,013.8
+ Other Comprehensive Income14.9-24.0287.4359.1
Total Comprehensive Income1,403.21,859.41,705.91,503.8
Net Income to Common1,388.31,885.41,418.51,144.3
Minority Interest0.0-2.00.00.4
Per Share
Basic EPS77.34105.2679.2063.89
Diluted EPS77.34105.2679.2063.89
Other Comprehensive Income — detail
+ Other Comprehensive Income-24.0287.4359.1
+ Items NOT to be Reclassified to P&L7.6-3.440.344.6
+ Items to be Reclassified to P&L7.3-20.6247.1314.5
Comprehensive Income — Owners of Parent1,403.21,861.41,705.91,503.4
Comprehensive Income — Non-controlling Interests0.0-2.00.00.4
Per Share — as-filed variants
Basic EPS — Continuing Operations77.34105.2679.2063.89
Diluted EPS — Continuing Operations77.34105.2679.2063.89
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit3,282.23,739.73,387.82,879.6
Gross Margin %82.0884.4383.0782.64
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,673.52,291.41,490.81,104.5
Net Income Adj (tax-effected)1,388.31,883.41,418.51,144.7
EPS Adj77.34105.2679.2063.89
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital35.835.835.835.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.